北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer
作者: Fang, Hong; Lin, Rong-Yan; Sun, Ming-Xia; Wang, Qian; Zhao, Yu-Liang; Yu, Jing-Lin; Tian, Yan; Wang, Xiao-Yun
关键词: NSCLC ; gefitinib ; cisplatin ; gemcitabine ; adenocarcinoma ; survival ; associated influencing factors
刊名: ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
发表日期: 2014
DOI: 10.7314/APJCP.2014.15.24.10967
卷: 15, 期:24, 页:10967-10970
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: PHASE-III ; CHEMOTHERAPY
英文摘要:

Objective: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced non-small cell lung cancer. Materials and Methods: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. Efficacy, survival time and adverse reactions were observed. The Kaplan-Meier method was adopted for analysis of survival and Cox regression for associated influencing factors. Results: The patients were followed up until October 31, 2013, and the median follow-up time was 19 months. Of 57 patients, there were 4 (7.0%) with complete remission (CR), 8 (14.0%) with partial remission, 31 (54.4%) with stable disease, and 14 (24.6%) with disease progression. The remission rate was 21.1% and the disease control rate was 75.4%. The median progression-free survival (PFS) time and the median overall survival time were 10 months and 15.2 months. The one-year, two-year and three-year survival rates were 47.4%, 23.3% and 10.0%. Gender and pathological types were the independent risk factors influencing PFS time (P=0.028, P=0.009). Tumor pathological type and early efficacy were independent factors for the prognosis (P=0.018, P=0.000). Adverse reactions were mostly rashes of I similar to II degree and diarrhea and slightly increasing level of aminopherase. The skin adverse event incidence of. degree or above was 1.8% (1/57) and brain metastasis was foudn in 31.6% (18/57). Conclusions: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb similar to IV NSCLC who received multiple cycles of chemotherapy.

语种: 英语
WOS记录号: WOS:000351058900072
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65811
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Dept Oncol Chemotherapy, Hosp 1, Beijing 100871, Peoples R China

Recommended Citation:
Fang, Hong,Lin, Rong-Yan,Sun, Ming-Xia,et al. Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer[J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION,2014,15(24):10967-10970.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Fang, Hong]'s Articles
[Lin, Rong-Yan]'s Articles
[Sun, Ming-Xia]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Fang, Hong]‘s Articles
[Lin, Rong-Yan]‘s Articles
[Sun, Ming-Xia]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace